We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

GT Biopharma Inc (GTBP) USD0.001

Sell:$3.82 Buy:$4.53 Change: $0.13 (2.95%)
Market closed |  Prices as at close on 4 March 2024 | Switch to live prices |
Sell:$3.82
Buy:$4.53
Change: $0.13 (2.95%)
Market closed |  Prices as at close on 4 March 2024 | Switch to live prices |
Sell:$3.82
Buy:$4.53
Change: $0.13 (2.95%)
Market closed |  Prices as at close on 4 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patients own natural killer cells (NK) cells. GTB-3550 is its TriKE product candidate which is a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The GTB-3550 Phase 1 clinical trial for treatment of patients with CD33-expression. It is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease, such as for the treatment of patients infected by the human immunodeficiency virus.

Contact details

Address:
8000 MARINA BLVD, SUITE 100
BRISBANE
94005
United States
Telephone:
+1 (310) 5514020
Website:
https://www.gtbiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GTBP
ISIN:
US36254L3087
Market cap:
$6.07 million
Shares in issue:
1.38 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Breen
    Executive Chairman of the Board, Interim Chief Executive Officer
  • Manu Ohri
    Chief Financial Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.